Rigel Pharmaceuticals Inc. (New) (RIGL) is a publicly traded Healthcare sector company. As of November 5, 2026, RIGL trades at $45.02 with a market cap of $958.09M and a P/E ratio of 2.69. RIGL moved -11.39% today. Year to date, RIGL is +10.60%; over the trailing twelve months it is +20.36%. Its 52-week range spans $15.50 to $52.61. Analyst consensus is buy with an average price target of $65.00. Rallies surfaces RIGL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rigel Q3 revenue reaches $80.9 million; 2026 outlook is $290 million to $295 million: Rigel’s third-quarter revenue rose 16% year over year to $80.9 million, slightly above the $80.1 million consensus estimate, while net income fell 53% to $13.19 million. The company expects 2026 total revenue of $290 million to $295 million, including VEPPANU.
| Metric | Value |
|---|---|
| Price | $45.02 |
| Market Cap | $958.09M |
| P/E Ratio | 2.69 |
| EPS | $17.83 |
| Dividend Yield | 0.00% |
| 52-Week High | $52.61 |
| 52-Week Low | $15.50 |
| Volume | 439.97K |
| Avg Volume | 0 |
| Revenue (TTM) | $276.79M |
| Net Income | $321.91M |
| Gross Margin | 91.39% |
4 analysts cover RIGL: 0 strong buy, 2 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $65.00.